查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813962

美国活性药物成分市场规模、份额和趋势分析报告：按合成类型、製造商、类型、应用和细分市场预测，2025-2033 年

U.S. Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis (Biotech, Synthetic), By Type Of Manufacturer (Captive, Mesrchant), By Type, By Application, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国活性药物成分市场摘要

预计 2024 年美国活性药物成分市场价值将达到 874.6 亿美元，到 2033 年将达到 1,319.8 亿美元，2025 年至 2033 年的复合年增长率为 4.6%。

癌症、心血管疾病、糖尿病和呼吸系统疾病等慢性疾病的发生率不断上升，推动着市场成长。受这些疾病影响的患者群体不断扩大，推动了对先进疗法的持续需求，包括小分子和生物製药的活性药物成分(原料药)。随着人口老化，需要长期治疗的老年人比例稳步上升，这使得 API 成为医疗保健管理的关键组成部分。例如，2025 年 8 月，唐纳德·川普总统签署了一项行政命令，建立战略原料药储备 (SAPIR)，以储存对国家健康和安全至关重要的药物成分。这项由美国卫生与公共服务部支持的倡议突显了 COVID-19 大流行暴露的供应链漏洞。

推动美国活性药物成分市场发展的另一个关键因素是生技药品和生物相似药的快速扩张，它们正在重塑各个治疗领域的治疗方法。单株抗体、重组蛋白和疫苗等生物製剂需要高度复杂、高价值的生技药品原料药比传统的小分子原料药更难製造。不断上涨的医疗成本加速了人们采用生物相似药作为具有成本效益的替代品，为原料药製造商提供了新的成长途径。随着肿瘤学、免疫学和罕见疾病需求的不断增长，製造商正在采用生物製程优化和细胞培养创新等先进技术。例如，2024 年 1 月，FDA 发布了指南草案，将人用药物的 CGMP 要求（ICH Q7）扩展到原料药，加强了监管并统一了标准。这项转变强调创新，并使美国公司成为全球生技药品供应链的领导者。

美国活性药物成分市场在很大程度上受到严格的法律规范的影响，这些监督旨在确保产品品质、安全性和一致性。遵守FDA标准对于维护信任和推动生产实践的持续改进至关重要。例如，2024年6月，美国食品药物管理局（FDA）修订了21 CFR第211部分，以加强原料药（包括活性药物成分）的品质保证，并增强现行良好生产规范（CGMP），确保原料药符合最高的安全性和有效性标准。这些监管更新鼓励製造商采用先进的系统，从而增强了美国活性药物成分行业的可信度和公信力。

这些监管改进措施预计将透过提高生产透明度和一致性来支持美国原料药市场的长期成长。更新后的CGMP框架鼓励製造商实施更强大的品管机制、先进的监控技术和标准化的操作程序。这不仅降低了污染和产品召回的风险，也提高了大规模生产的效率。透过使行业实践与更高的品质基准保持一致，FDA正在创造一个企业能够透过创新竞争同时确保患者安全的环境。因此，製药公司可以放心地扩展产品系列。整体而言，这些措施增强了美国原料药在国内和全球供应链中的可靠性。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国活性药物成分市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章美国活性药物成分市场：合成型业务分析

  • 2024年及2033年合成橡胶市场份额
  • 综合细分仪表板的类型
  • 2021 年至 2033 年按合成类型分類的市场规模、预测与趋势分析
  • 生物技术
  • 合成

第五章美国活性药物成分市场：按製造商类型进行的业务分析

  • 2024 年及 2033 年各製造商市场份额
  • 製造商类型细分仪表板
  • 市场规模、预测和趋势分析（按製造商类型，2021-2033 年）
  • 专属式API
  • 商家 API
  • 商家 API 市集（按类型）
  • 商家 API 市场（依合成类型）

第六章美国活性药物成分市场：按类型分類的业务分析

  • 2024 年及 2033 年各类型市场份额
  • 类型细分仪表板
  • 市场规模、预测与趋势分析（按类型，2021-2033 年）
  • 通用 API
  • 创新 API

第七章美国活性药物成分市场：应用业务分析

  • 2024 年和 2033 年应用市场份额
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2021-2033 年）
  • 心臟病学
  • 肿瘤学
  • 中枢神经系统和神经病学
  • 整形外科
  • 内分泌学
  • 呼吸系统医疗设备
  • 胃肠病学
  • 肾臟病学
  • 眼科
  • 其他的

第八章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • AbbVie Inc.
    • Viatris Inc.
    • Fresenius Kabi AG
    • Curia
    • Pfizer Inc.（Pfizer Center One）
    • Bristol-Myers Squibb Company
    • Catalent, Inc.
    • Ampac Fine Chemicals（AFC）
    • Amgen Inc.
    • Johnson &Johnson
Product Code: GVR-4-68040-309-1

U.S. Active Pharmaceutical Ingredients Market Summary

The U.S. active pharmaceutical ingredients market size was estimated at USD 87.46 billion in 2024, is projected to reach USD 131.98 billion by 2033, growing at a CAGR of 4.6% from 2025 to 2033. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, diabetes, and respiratory illnesses drives the market growth. The expanding patient pool suffering from these conditions are fueling sustained demand for advanced therapies, including both small-molecule and biologic APIs. With an aging demographic, the proportion of elderly individuals requiring long-term treatment is steadily increasing, positioning APIs as a cornerstone of healthcare management. For instance, in August 2025, President Donald Trump signed an executive order establishing the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to stockpile critical drug components for national health and security. Supported by the U.S. Department of Health and Human Services, this initiative highlighted supply chain vulnerabilities exposed by the COVID-19 pandemic.

Another key factor driving the U.S. active pharmaceutical ingredients market is the rapid expansion of biologics and biosimilars, which are reshaping treatment approaches across therapeutic areas. Biologics such as monoclonal antibodies, recombinant proteins, and vaccines require highly complex, high-value APIs that are more difficult to manufacture than conventional small-molecule APIs. Rising healthcare costs have accelerated the adoption of biosimilars as cost-effective alternatives, creating new growth avenues for API producers. As demand increases across oncology, immunology, and rare diseases, manufacturers are adopting advanced techniques such as bioprocess optimization and cell culture innovation. For instance, in January 2024, the FDA issued draft guidance extending human drug CGMP requirements (ICH Q7) to veterinary APIs, strengthening oversight and aligning standards. This shift underscores innovation and positions U.S.-based firms as global biologics supply chain leaders.

The U.S. active pharmaceutical ingredients market is heavily shaped by stringent regulatory oversight that ensures product quality, safety, and consistency. Compliance with FDA standards plays a critical role in maintaining trust and driving continuous improvements in manufacturing practices. For instance, in June 2024, the U.S. Food and Drug Administration (FDA) amended 21 CFR Part 211, enhancing Current Good Manufacturing Practices (CGMP) for drug products, including APIs, to strengthen quality assurance and ensure APIs meet the highest standards of safety and efficacy. Such regulatory updates push manufacturers to adopt advanced systems, reinforcing the credibility and reliability of the U.S. API industry.

These regulatory enhancements are expected to support long-term growth in the U.S. API market by fostering greater transparency and consistency in production. The updated CGMP framework encourages manufacturers to implement more robust quality-control mechanisms, advanced monitoring technologies, and standardized operating procedures. This not only reduces the risk of contamination and product recalls but also improves efficiency in large-scale manufacturing. By aligning industry practices with higher quality benchmarks, the FDA creates an environment where companies can compete through innovation while ensuring patient safety. In turn, pharmaceutical firms are better positioned to confidently expand their product portfolios. Overall, these measures strengthen the reliability of U.S.-produced APIs in both domestic and global supply chains.

U.S. Active Pharmaceutical Ingredients Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, and application.

  • Type of Synthesis Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biotech
    • Biotech APIs Market, By Type
    • Generic API
    • Innovative API
    • Biotech APIs Market, By Product
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Recombinant Proteins
    • Therapeutic Enzymes
    • Vaccines
    • Blood Factors
  • Synthetic
    • Synthetic APIs Market, By Type
    • Generic API
    • Innovative API
  • Type of Manufacturer Outlook (Revenue, USD Billion, 2021 - 2033)
  • Captive APIs
  • Merchant APIs
    • Merchant APIs Market, By Type
    • Generic API
    • Innovative API
    • Merchant APIs Market, By Type of Synthesis
    • Biotech
    • Synthetic
  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Generic API
  • Innovative API
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cardiology
  • Oncology
  • CNS and Neurology
  • Orthopedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type of Synthesis
    • 1.2.2. Type of Manufacturer
    • 1.2.3. Type
    • 1.2.4. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Source
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Source
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Active Pharmaceutical Ingredients Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Active Pharmaceutical Ingredients Market: Type of Synthesis Business Analysis

  • 4.1. Type of Synthesis Market Share, 2024 & 2033
  • 4.2. Type of Synthesis Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type of Synthesis, 2021 to 2033 (USD Billion)
  • 4.4. Biotech
    • 4.4.1. Biotech Market, 2021 - 2033 (USD Billion)
    • 4.4.2. Biotech APIs Market, By Type
      • 4.4.2.1. Biotech APIs Market, By Type Market, 2021 - 2033 (USD Billion)
      • 4.4.2.2. Generic API
        • 4.4.2.2.1. Generic API Market, 2021 - 2033 (USD Billion)
      • 4.4.2.3. Innovative API
        • 4.4.2.3.1. Innovative API Market, 2021 - 2033 (USD Billion)
    • 4.4.3. Biotech APIs Market, By Product
      • 4.4.3.1. Biotech APIs Market, By Product Market, 2021 - 2033 (USD Billion)
      • 4.4.3.2. Monoclonal Antibodies
        • 4.4.3.2.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Billion)
      • 4.4.3.3. Hormones
        • 4.4.3.3.1. Hormones Market, 2021 - 2033 (USD Billion)
      • 4.4.3.4. Cytokines
        • 4.4.3.4.1. Cytokines Market, 2021 - 2033 (USD Billion)
      • 4.4.3.5. Recombinant Proteins
        • 4.4.3.5.1. Recombinant Proteins Market, 2021 - 2033 (USD Billion)
      • 4.4.3.6. Therapeutic Enzymes
        • 4.4.3.6.1. Therapeutic Enzymes Market, 2021 - 2033 (USD Billion)
      • 4.4.3.7. Vaccines
        • 4.4.3.7.1. Vaccines Market, 2021 - 2033 (USD Billion)
      • 4.4.3.8. Blood Factors
        • 4.4.3.8.1. Blood Factors Market, 2021 - 2033 (USD Billion)
  • 4.5. Synthetic
    • 4.5.1. Synthetic Market, 2021 - 2033 (USD Billion)
    • 4.5.2. Synthetic APIs Market, By Type
      • 4.5.2.1. Synthetic APIs Market, By Type Market, 2021 - 2033 (USD Billion)
      • 4.5.2.2. Generic API
        • 4.5.2.2.1. Generic API Market, 2021 - 2033 (USD Billion)
      • 4.5.2.3. Innovative API
        • 4.5.2.3.1. Innovative API Market, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Active Pharmaceutical Ingredients Market: Type of Manufacturer Business Analysis

  • 5.1. Type of Manufacturer Market Share, 2024 & 2033
  • 5.2. Type of Manufacturer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type of Manufacturer, 2021 to 2033 (USD Billion)
  • 5.4. Captive APIs
    • 5.4.1. Captive APIs Market, 2021 - 2033 (USD Billion)
  • 5.5. Merchant APIs
    • 5.5.1. Merchant APIs Market, 2021 - 2033 (USD Billion)
  • 5.6. Merchant APIs Market, By Type
    • 5.6.1. Merchant APIs Market, By Type Market, 2021 - 2033 (USD Billion)
    • 5.6.2. Generic API
      • 5.6.2.1. Generic API Market, 2021 - 2033 (USD Billion)
    • 5.6.3. Innovative API
      • 5.6.3.1. Innovative API Market, 2021 - 2033 (USD Billion)
  • 5.7. Merchant APIs Market, By Type of Synthesis
    • 5.7.1. Merchant APIs Market, By Type of Synthesis Market, 2021 - 2033 (USD Billion)
    • 5.7.2. Biotech
      • 5.7.2.1. Biotech Market, 2021 - 2033 (USD Billion)
    • 5.7.3. Synthetic
      • 5.7.3.1. Synthetic Market, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Active Pharmaceutical Ingredients Market: Type Business Analysis

  • 6.1. Type Market Share, 2024 & 2033
  • 6.2. Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
  • 6.4. Generic API
    • 6.4.1. Generic API Market, 2021 - 2033 (USD Billion)
  • 6.5. Innovative API
    • 6.5.1. Innovative API Market, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Active Pharmaceutical Ingredients Market: Application Business Analysis

  • 7.1. Application Market Share, 2024 & 2033
  • 7.2. Application Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Billion)
  • 7.4. Cardiology
    • 7.4.1. Cardiology Market, 2021 - 2033 (USD Billion)
  • 7.5. Oncology
    • 7.5.1. Oncology Market, 2021 - 2033 (USD Billion)
  • 7.6. CNS and Neurology
    • 7.6.1. CNS and Neurology Market, 2021 - 2033 (USD Billion)
  • 7.7. Orthopedic
    • 7.7.1. Orthopedic Market, 2021 - 2033 (USD Billion)
  • 7.8. Endocrinology
    • 7.8.1. Endocrinology Market, 2021 - 2033 (USD Billion)
  • 7.9. Pulmonology
    • 7.9.1. Pulmonology Market, 2021 - 2033 (USD Billion)
  • 7.10. Gastroenterology
    • 7.10.1. Gastroenterology Market, 2021 - 2033 (USD Billion)
  • 7.11. Nephrology
    • 7.11.1. Nephrology Market, 2021 - 2033 (USD Billion)
  • 7.12. Ophthalmology
    • 7.12.1. Ophthalmology Market, 2021 - 2033 (USD Billion)
  • 7.13. Others
    • 7.13.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Viatris Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fresenius Kabi AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Curia
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc. (Pfizer Center One)
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Bristol-Myers Squibb Company
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Catalent, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Ampac Fine Chemicals (AFC)
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Amgen Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Johnson & Johnson
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. active pharmaceutical ingredients market, by Type of Synthesis, 2021 - 2033 (USD Billion)
  • Table 4. U.S. active pharmaceutical ingredients market, by Type of Manufacturer, 2021 - 2033 (USD Billion)
  • Table 5. U.S. active pharmaceutical ingredients market, by Type, 2021 - 2033 (USD Billion)
  • Table 6. U.S. active pharmaceutical ingredients market, by Application, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 U.S. active pharmaceutical ingredients market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 U.S. active pharmaceutical ingredients market dynamics
  • Fig. 11 U.S. active pharmaceutical ingredients market: Porter's five forces analysis
  • Fig. 12 U.S. active pharmaceutical ingredients market: PESTLE analysis
  • Fig. 13 Type of Synthesis market, 2021 - 2033 (USD Billion)
  • Fig. 14 Biotech market, 2021 - 2033 (USD Billion)
  • Fig. 15 Biotech APIs Market, By Type market, 2021 - 2033 (USD Billion)
  • Fig. 16 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 17 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 18 Biotech APIs Market, By Product market, 2021 - 2033 (USD Billion)
  • Fig. 19 Monoclonal Antibodies market, 2021 - 2033 (USD Billion)
  • Fig. 20 Hormones market, 2021 - 2033 (USD Billion)
  • Fig. 21 Cytokines market, 2021 - 2033 (USD Billion)
  • Fig. 22 Recombinant Proteins market, 2021 - 2033 (USD Billion)
  • Fig. 23 Therapeutic Enzymes market, 2021 - 2033 (USD Billion)
  • Fig. 24 Vaccines market, 2021 - 2033 (USD Billion)
  • Fig. 25 Blood Factors market, 2021 - 2033 (USD Billion)
  • Fig. 26 Synthetic market, 2021 - 2033 (USD Billion)
  • Fig. 27 Synthetic APIs Market, By Type market, 2021 - 2033 (USD Billion)
  • Fig. 28 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 29 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 30 Type of Manufacturer market, 2021 - 2033 (USD Billion)
  • Fig. 31 Captive APIs market, 2021 - 2033 (USD Billion)
  • Fig. 32 Merchant APIs market, 2021 - 2033 (USD Billion)
  • Fig. 33 Merchant APIs Market, By Type market, 2021 - 2033 (USD Billion)
  • Fig. 34 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 35 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 36 Merchant APIs Market, By Type of Synthesis market, 2021 - 2033 (USD Billion)
  • Fig. 37 Biotech market, 2021 - 2033 (USD Billion)
  • Fig. 38 Synthetic market, 2021 - 2033 (USD Billion)
  • Fig. 39 Type market, 2021 - 2033 (USD Billion)
  • Fig. 40 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 41 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 42 Application market, 2021 - 2033 (USD Billion)
  • Fig. 43 Cardiology market, 2021 - 2033 (USD Billion)
  • Fig. 44 Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 45 CNS and Neurology market, 2021 - 2033 (USD Billion)
  • Fig. 46 Orthopedic market, 2021 - 2033 (USD Billion)
  • Fig. 47 Endocrinology market, 2021 - 2033 (USD Billion)
  • Fig. 48 Pulmonology market, 2021 - 2033 (USD Billion)
  • Fig. 49 Gastroenterology market, 2021 - 2033 (USD Billion)
  • Fig. 50 Nephrology market, 2021 - 2033 (USD Billion)
  • Fig. 51 Ophthalmology market, 2021 - 2033 (USD Billion)
  • Fig. 52 Others market, 2021 - 2033 (USD Billion)